International Stem Cell Corporation
ISCO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.29 | -0.02 | 0.00 | -0.14 |
| FCF Yield | 4.42% | -25.92% | 23.11% | -11.83% |
| EV / EBITDA | 5.96 | 19.03 | -22.52 | 31.35 |
| Quality | ||||
| ROIC | 9.31% | 3.93% | -4.99% | 1.21% |
| Gross Margin | 55.76% | 62.12% | 53.41% | 59.53% |
| Cash Conversion Ratio | 0.86 | -2.33 | -0.89 | -6.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.08% | 4.51% | 3.28% | 3.56% |
| Free Cash Flow Growth | 113.86% | -249.55% | 388.31% | -135.00% |
| Safety | ||||
| Net Debt / EBITDA | -5.11 | 13.24 | -16.52 | 25.10 |
| Interest Coverage | -94.00 | 4.39 | -5.24 | 1.31 |
| Efficiency | ||||
| Inventory Turnover | 0.66 | 0.60 | 0.79 | 0.86 |
| Cash Conversion Cycle | 152.43 | 154.35 | 108.65 | 126.47 |